Three years of tirzepatide also reduced risk for progression to type 2 diabetes compared with placebo<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Nov. 18, 2024 (HealthDay News) — For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study published online Nov. 13 in the New England Journal of Medicine<\/em>.<\/p>\n Ania M. Jastreboff, M.D., Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues performed a phase 3, double-blind trial involving 2,539 participants with obesity (1,032 of whom also had prediabetes), who were randomly assigned to receive tirzepatide at a once-weekly dose of 5, 10, or 15 mg or placebo in a 1:1:1:1 ratio. The current analysis included the participants with obesity and prediabetes who received tirzepatide or placebo for 176 weeks followed by an off-treatment period of 17 weeks.<\/p>\n The researchers found that the mean percentage change in body weight at 176 weeks was \u221212.3, \u221218.7, and \u221219.7 percent for those receiving 5-, 10-, and 15-mg tirzepatide doses, respectively, compared with \u22121.3 percent for those receiving placebo. Receipt of a diagnosis of type 2 diabetes occurred in fewer participants in the tirzepatide groups versus the placebo group (1.3 versus 13.3 percent; hazard ratio, 0.07). After 17 weeks off treatment, 2.4 and 13.7 percent of those who received tirzepatide and placebo, respectively, had type 2 diabetes (hazard ratio, 0.12). Apart from COVID-19, the most common adverse events were gastrointestinal, most of which were mild-to-moderate in severity.<\/p>\n “Tirzepatide therapy resulted in sustained weight reduction that was accompanied by a markedly lower risk of progression to type 2 diabetes than that with placebo,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n